Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Ocular Therapeut (OCUL)

Ocular Therapeut (OCUL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,332,878
  • Shares Outstanding, K 75,861
  • Annual Sales, $ 4,230 K
  • Annual Income, $ -86,370 K
  • 60-Month Beta 2.20
  • Price/Sales 78.95
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade OCUL with:

Options Overview

Details
  • Implied Volatility 97.20%
  • Historical Volatility 56.66%
  • IV Percentile 24%
  • IV Rank 9.94%
  • IV High 282.72% on 04/17/20
  • IV Low 76.71% on 11/06/20
  • Put/Call Vol Ratio 1.50
  • Today's Volume 405
  • Volume Avg (30-Day) 786
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 6,002
  • Open Int (30-Day) 10,427

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.18
  • Number of Estimates 4
  • High Estimate -0.15
  • Low Estimate -0.23
  • Prior Year -0.47
  • Growth Rate Est. (year over year) +61.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.56 +4.65%
on 02/23/21
21.02 -17.55%
on 02/11/21
-1.60 (-8.45%)
since 02/04/21
3-Month
16.56 +4.65%
on 02/23/21
24.30 -28.68%
on 12/16/20
-3.01 (-14.80%)
since 12/04/20
52-Week
3.78 +359.07%
on 03/13/20
24.30 -28.68%
on 12/16/20
+10.10 (+139.70%)
since 03/04/20

Most Recent Stories

More News
Ocular Therapeutix(TM) Announces FDA Acceptance of Supplemental New Drug Application for DEXTENZA(R) (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

Ocular Therapeutix, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 17.33 (-1.37%)
Will Ocular Therapeutix (OCUL) Report Negative Earnings Next Week? What You Should Know

Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OCUL : 17.33 (-1.37%)
Ocular Therapeutix(TM) Announces First Patient Dosed in Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease

Ocular Therapeutix(TM), Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 17.33 (-1.37%)
Ocular Therapeutix(TM) To Report Fourth Quarter and Year End 2020 Financial Results

Ocular Therapeutix(TM), Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 17.33 (-1.37%)
Global $60+ Billion Ophthalmic Drugs Market to 2028: Patent Expiry Of Blockbuster Drugs to Limit Market growth

, /PRNewswire/ -- The report has been added to offering.

OCUL : 17.33 (-1.37%)
DGX : 117.28 (+0.34%)
Ocular Therapeutix(TM) to Participate at Three Upcoming Investor Conferences

Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 17.33 (-1.37%)
Thinking about buying stock in Salarius Pharmaceuticals, KemPharm, Ocular Therapeutix, Boxlight Corp, or Endra Life Sciences?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SLRX, KMPH, OCUL, BOXL, and NDRA.

KMPH : 9.63 (-28.51%)
OCUL : 17.33 (-1.37%)
SLRX : 1.3500 (-16.15%)
BOXL : 2.18 (-12.10%)
NDRA : 2.13 (-13.41%)
Ocular Therapeutix(TM) Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition

Ocular Therapeutix(TM), Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced...

OCUL : 17.33 (-1.37%)
Ocular Drug Delivery Mode Market Size Detailed Analysis of Current Industry Figures with Forecasts Growth By 2025

Selbyville, Delaware. The report on Ocular Drug Delivery Mode market is a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections...

ALIM : 7.66 (-6.59%)
CLSD : 3.25 (-5.25%)
OCUL : 17.33 (-1.37%)
VRX.TO : 30.80 (-3.33%)
Ocular Therapeutix(TM) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 17.33 (-1.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular...

See More

Key Turning Points

3rd Resistance Point 19.35
2nd Resistance Point 18.76
1st Resistance Point 18.04
Last Price 17.33
1st Support Level 16.73
2nd Support Level 16.14
3rd Support Level 15.42

See More

52-Week High 24.30
Last Price 17.33
Fibonacci 61.8% 16.46
Fibonacci 50% 14.04
Fibonacci 38.2% 11.62
52-Week Low 3.78

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar